Diabetes and the brain: Issues and unmet needs

Neurological Sciences

Volumn 35, Issue 7, 2014, Pages 995-1001

  Bornstein, Natan M ^a   Brainin, Michael ^b   Guekht, Alla ^c   Skoog, Ingmar ^d   Korczyn, Amos D ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b DANUBE UNIVERSITY KREMS   (Austria)

^c PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Cognitive impairment; Diabetes; Stroke; Vascular dementia

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACTOVEGIN; ADVANCED GLYCATION END PRODUCT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; CEREBROLYSIN; DONEPEZIL; GALANTAMINE; INDAPAMIDE; MEMANTINE; PERINDOPRIL; PLACEBO; ROSIGLITAZONE;

ALZHEIMER DISEASE; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; BRAIN BLOOD VESSEL; BRAIN DISEASE; BRAIN INFARCTION; BRAIN ISCHEMIA; BRAIN SIZE; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; COGNITIVE DEFECT; DEMENTIA; DIABETES MELLITUS; DIABETIC NEUROPATHY; DIGIT SYMBOL SUBSTITUTION TEST; GLUCOSE METABOLISM; GLUCOTOXICITY; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN RESISTANCE; INSULIN TREATMENT; MILD COGNITIVE IMPAIRMENT; MULTIINFARCT DEMENTIA; NERVE DEGENERATION; NEUROPATHOLOGY; OXIDATIVE STRESS; REVIEW; RISK FACTOR; BRAIN; COGNITION DISORDERS; PATHOLOGY;

BRAIN; COGNITION DISORDERS; DIABETES COMPLICATIONS; DIABETES MELLITUS; HUMANS;

EID: 84903278983     PISSN: 15901874     EISSN: 15903478     Source Type: Journal    
DOI: 10.1007/s10072-014-1797-2     Document Type: Review

References (60)

1. Gorelick PB, Scuteri A, Black SE et al (2011) Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 42:2672-2713
2. Whiting DR, Guariguata L, Weil C et al (2011) IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 94:3113-3121
3. Korczyn AD (2002) Mixed dementia - the most common cause of dementia. Ann N Y Acad Sci 977:129-134
4. Schneider JA, Bennett DA (2010) Where vascular meets neurodegenerative disease. Stroke 41(10 Suppl):S144-S146
5. Biessels GJ, Staekenborg S, Brunner E et al (2006) Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol 5:64-74
6. Exalto LG, Whitmer RA, Kappele LJ et al (2012) An update on type 2 diabetes, vascular dementia and Alzheimer's disease. Exp Gerontol 47:858-864
7. Brands AM, Van den Berg E, Manschot SM et al (2007) A detailed profile of cognitive dysfunction and its relation to psychological distress in patients with type 2 diabetes mellitus. J Int Neuropsychol Soc 13:288-297
8. Knopman D, Boland LL, Mosley T et al (2001) Cardiovascular risk factors and cognitive decline in middle-aged adults. Neurology 56:42-48
9. Arntzen KA, Schirmer H, Wilsgaard T et al (2011) Impact of cardiovascular risk factors on cognitive function: the Tromsø study. Eur J Neurol 18:737-743
10. Crane PK, Walker R, Hubbard RA et al (2013) Glucose levels and risk of dementia. N Engl J Med 369:540-548
11. Kerti L, Witte AV, Winkler A et al (2013) Higher glucose levels associated with lower memory and reduced hippocampal microstructure. Neurology 81:1746-1752
12. Ruis C, Biessels GJ, Gorter KJ et al (2009) Cognition in the early stage of type 2 diabetes. Diabetes Care 32:1261-1265
13. Yates KF, Sweat V, Yau PL et al (2012) Impact of metabolic syndrome on cognition and brain: a selected review of the literature. Arterioscler Thromb Vasc Biol 32:2060-2067
14. Cheng G, Huang C, Deng H et al (2012) Diabetes as a risk factor for dementia and mild cognitive impairment: a meta-analysis of longitudinal studies. Intern Med J 42:484-491
15. Ahtiluoto S, Polvikoski T, Peltonen M et al (2010) Diabetes, Alzheimer disease, and vascular dementia: a population-based neuropathologic study. Neurology 75:1195-1202
16. Reijmer YD, van den Berg E, Ruis C et al (2010) Cognitive dysfunction in patients with type 2 diabetes. Diabetes Metab Res Rev 26:507-519
17. Strachan MW, R D Lawrence Lecture 2010 (2011) The brain as a target organ in type 2 diabetes: exploring the links with cognitive impairment and dementia. Diabet Med 28:141-147
18. Vermeer SE, Den Heijer T, Koudstaal PJ, Rotterdam Scan Study et al (2003) Incidence and risk factors of silent brain infarcts in the population-based Rotterdam scan study. Stroke 34:392-396
19. Gouw AA, van der Flier WM, Fazekas F et al (2008) Progression of white matter hyperintensities and incidence of new lacunes over a 3-year period: the leukoaraiosis and disability study. Stroke 39:1414-1420
20. Sarwar N, Gao P, Emerging Risk Factors Collaboration et al (2010) Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 375:2215-2222
21. Eriksson M, Carlberg B, Eliasson M (2012) The disparity in long-term survival after a first stroke in patients with and without diabetes persists: the Northern Sweden MONICA study. Cerebrovasc Dis 34:153-160
22. Matz K, Keresztes K, Tatschl C et al (2006) Disorders of glucose metabolism in acute stroke patients: an under recognized problem. Diabetes Care 29:792-797
23. Brainin M, Matz K, Teuschl Y et al (2009) The hidden burden of glucose pathology in acute stroke remains hidden. Stroke 40:e3
24. Capes SE, Hunt D, Malmberg K et al (2001) Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview. Stroke 32:2426-2432
25. Alvarez-Sabín J, Molina CA, Montaner J et al (2003) Effects of admission hyperglycemia on stroke outcome in reperfused tissue plasminogen activator-treated patients. Stroke 34:1235-1241
26. Bruno A, Levine SR, Frankel MR et al (2002) Admission glucose level and clinical outcomes in the NINDS rt-PA stroke trial. Neurology 59:669-674
27. Kruyt ND, Biessels GJ, Devries JH et al (2010) Hyperglycemia in acute ischemic stroke: pathophysiology and clinical management. Nat Rev Neurol 6:145-155
28. Uyttenboogaart M, Koch MW, Stewart RE et al (2007) Moderate hyperglycaemia is associated with favourable outcome in acute lacunar stroke. Brain 130(Pt 6):1626-1630
29. van den Berghe G, Wouters P, Weekers F et al (2001) Intensive insulin therapy in critically ill patients. N Engl J Med 345:1359-1367
30. Finfer S, Chittock DR, NICE-SUGAR Study Investigators et al (2009) Intensive versus conventional glucose control in critically ill patients. N Engl J Med 360:1283-1297
31. Kansagara D, Fu R, Freeman M, Wolf F, Helfand M (2011) Intensive insulin therapy in hospitalized patients: a systematic review. Ann Intern Med 154:268-282
32. Gray CS, Hildreth AJ, Sandercock PA et al (2007) Glucose-potassium- insulin infusions in the management of post-stroke hyperglycaemia: the UK glucose insulin in stroke trial (GIST-UK). Lancet Neurol 6:397-406
33. Bruno A, Kent TA, Coull BM et al (2008) Treatment of hyperglycemia in ischemic stroke (THIS): a randomized pilot trial. Stroke 39:384-389
34. Southerland AM, Johnston KC (2012) Considering hyperglycemia and thrombolysis in the stroke hyperglycemia insulin network effort (SHINE) trial. Ann N Y Acad Sci 1268:72-78
35. Ligthart SA, Moll van Charante EP et al (2010) Treatment of cardiovascular risk factors to prevent cognitive decline and dementia: a systematic review. Vasc Health Risk Manag 6:775-785
36. Tzourio C, Anderson C, Chapman N et al (2003) Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 163:1069-1075
37. Peters R, Beckett N, Forette F et al (2008) Incident dementia and blood pressure lowering in the hypertension in the very elderly trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol 7:683-689
38. Prince MJ, Bird AS, Blizard RA et al (1996) Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's treatment trial of hypertension in older adults. BMJ 312:801-805
39. Lithell H, Hansson L, Skoog I et al (2003) The study on cognition and prognosis in the elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 21:875-886
40. Heart Protection Study Collaborative Group (2002) MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo controlled trial. Lancet 360:7-22
41. Shepherd J, Blauw GJ, Murphy MB, PROspective Study of Pravastatin in the Elderly at Risk et al (2002) Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360:1623-1630
42. Ryan CM, Freed MI, Rood JA et al (2006) Improving metabolic control leads to better working memory in adults with type 2 diabetes. Diabetes Care 29:345-351
43. Luchsinger JA, Palmas W, Teresi JA et al (2011) Improved diabetes control in the elderly delays global cognitive decline. J Nutr Health Aging 15:445-459
44. Jacobson AM, Musen G, Ryan CM et al (2007) Long-term effect of diabetes and its treatment on cognitive function. N Engl J Med 356:1842-1852
45. Koekkoek PS, Ruis C, van den Donk M et al (2012) Intensive multifactorial treatment and cognitive functioning in screen-detected type 2 diabetes-the ADDITION-Netherlands study: a cluster-randomized trial. J Neurol Sci 314:71-77
46. Launer LJ, Miller ME, Williamson JD et al (2011) Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurol 10:969-977
47. Whitmer RA, Karter AJ, Yaffe K et al (2009) Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA 301:1565-1572
48. Risner ME, Saunders AM, Altman JF et al (2006) Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J 6:246-254
49. Harrington C, Sawchak S, Chiang C et al (2011) Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer's disease: two phase 3 studies. Curr Alzheimer Res 8:592-606
50. Seaquist ER, Miller ME, Fonseca V et al (2013) Effect of thiazolidinediones and insulin on cognitive outcomes in ACCORD-MIND. J Diabetes Complicat 27:485-491
51. Chen Y, Zhou K, Wang R et al (2009) Antidiabetic drug metformin (Glucophage) increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcription. Proc Natl Acad Sci USA 106:3907-3912
52. Moore EM, Mander AG, Ames D et al (2013) Increased risk of cognitive impairment in patients with diabetes is associated with metformin. Diabetes Care 36:2981-2987
53. Li J, Deng J, Sheng W, Zuo Z (2012) Metformin attenuates Alzheimer's disease-like neuropathology in obese, leptin-resistant mice. Pharmacol Biochem Behav 101:564-574
54. Black S, Román GC, Geldmacher DS et al (2003) Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke 34:2323-2330
55. Auchus AP, Brashear HR, Salloway S et al (2007) Galantamine treatment of vascular dementia: a randomized trial. Neurology 69:448-458
56. Korczyn AD, Vakhapova V, Grinberg LT (2012) Vascular dementia. J Neurol Sci 322:2-10
57. Guekht AB, Moessler H, Novak PH et al (2011) Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial. J Stroke Cerebrovasc Dis 20:310-318
58. Machicao F, Muresanu DF, Hundsberger H et al (2012) Pleiotropic neuroprotective and metabolic effects of Actovegin's mode of action. J Neurol Sci 5(322):222-227
59. Ziegler D, Movsesyan L, Mankovsky B et al (2009) Treatment of symptomatic polyneuropathy with Actovegin in type 2 diabetic patients. Diabetes Care 32:1479-1484
60. Guekht A, Skoog I, Korczyn AD et al (2013) A randomised, double-blind, placebo-controlled trial of Actovegin in patients with post-stroke cognitive impairment: ARTEMIDA study design. Dement Geriatr Cogn Disord Extra 3:459-467